Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
RevMab
anti-PD-1 (human), Rabbit Monoclonal (RM309)
Product Details | |
---|---|
Synonyms | CD279; Programmed Cell Death Protein 1 |
Product Type | Recombinant Antibody |
Properties | |
Clone | RM309 |
Isotype | Rabbit IgG |
Source/Host | Rabbit |
Immunogen/Antigen | A peptide corresponding to the N-terminus of human PD-1. |
Application |
Immunohistochemistry (IHC): 1:200-1:500 dilution |
Crossreactivity | Human |
Specificity |
This antibody reacts to human PD-1 (Programmed cell death protein 1) (CD279). |
Purity | Protein A purified. |
Purity Detail | Protein A affinity purified from an animal origin-free culture supernatant. |
Concentration | N/A |
Formulation | Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. |
Isotype Negative Control | |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Accession Number | Q15116 |
Declaration | Manufactured by RevMab Biosciences. |
Shipping and Handling | |
Shipping | BLUE ICE |
Long Term Storage | -20°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T cell regulators, expressed as a co-receptor on the surface of activated T cells, B cells and macrophages. Several studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to antitumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma and renal-cell cancer.